Literature DB >> 20961771

The efficacy of bipolar and multipolar radiofrequency ablation of lung neoplasms - results of an ablate and resect study.

Thomas Schneider1, David Reuss, Arne Warth, Philipp A Schnabel, Andreas von Deimling, Felix J F Herth, Hendrik Dienemann, Hans Hoffmann.   

Abstract

OBJECTIVE: Radiofrequency ablation (RFA) has obtained increasing attention as an interventional approach for the local treatment of primary and secondary lung neoplasms. The local effect of the procedure is usually controlled by radiologic means. The objectives of this 'ablate and resect' study were to investigate the efficacy of bipolar and multipolar RFA by histologic evaluation and to compare the two techniques.
METHODS: In a total of 32 subjects with histologically proven non-small-cell lung cancer or pulmonary metastases from an extrathoracic primary tumor, bipolar, or multipolar RFA was performed during open thoracotomy. Curative resection (lobectomy or wedge resection including mediastinal lymph node dissection) was performed subsequently. The extent of cell death and early histologic findings following RFA were determined by histology and immunohistochemistry (nicotinamide adenine dinucleotide (NADH) and monoclonal anti-mitochondrial antibodies MAB 1273).
RESULTS: Intra-operative bipolar and multipolar RFA is a safe procedure, and there was no bleeding or thermal damage of the lung tissue. Routine histologic staining could not identify tumor cell death. However, immunohistochemistry was able to verify cell death in the ablated tumor tissue. Complete tumor cell necrosis was determined in 12 tumors (37.5%); and scattered vital tumor tissue was detected in 16 tumors (50%). Incomplete ablation with a ratio of >20% vital tumor tissue was found in four tumors (12.5%), particularly surrounding vascular structures within the tumor tissue or in marginal zones of the tumor tissue. The local efficacy of bipolar and multipolar RFA was comparable, and incomplete ablations were found only in adenocarcinoma.
CONCLUSIONS: Bipolar and multipolar RFA in an open thoracotomy setting is a technically feasible and safe procedure. Early immunohistochemical findings after RFA showed complete tumor cell necrosis in 38% of cases. The high rate of viable tumor cells remaining after ablation casts doubt on RFA as a curative concept. This approach should be reserved for palliative indications. Patients fulfilling the criteria for curative resection should not be denied surgery.
Copyright © 2010 European Association for Cardio-Thoracic Surgery. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20961771     DOI: 10.1016/j.ejcts.2010.08.055

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  16 in total

1.  Computed tomography fluoroscopy-guided percutaneous 125I seed implantation for safe, effective and real-time monitoring radiotherapy of inoperable stage T1-3N0M0 non-small-cell lung cancer.

Authors:  Jiakai Li; Miao Yu; Yueyong Xiao; Li Yang; Jinshan Zhang; Erik Ray; Xiaoming Yang
Journal:  Mol Clin Oncol       Date:  2013-08-23

2.  Residual tumor after laser ablation of human non-small-cell lung cancer demonstrated by ex vivo staining: correlation with invasive temperature measurements.

Authors:  Christian Oliver Martin Hoffmann; Christian Rosenberg; Albert Linder; Norbert Hosten
Journal:  MAGMA       Date:  2011-06-09       Impact factor: 2.310

Review 3.  Thermal ablation of malignant lung tumors.

Authors:  Thomas Schneider; Claus Peter Heussel; Felix J F Herth; Hendrik Dienemann
Journal:  Dtsch Arztebl Int       Date:  2013-05-31       Impact factor: 5.594

4.  Image-guided tumor ablation: standardization of terminology and reporting criteria--a 10-year update.

Authors:  Muneeb Ahmed; Luigi Solbiati; Christopher L Brace; David J Breen; Matthew R Callstrom; J William Charboneau; Min-Hua Chen; Byung Ihn Choi; Thierry de Baère; Gerald D Dodd; Damian E Dupuy; Debra A Gervais; David Gianfelice; Alice R Gillams; Fred T Lee; Edward Leen; Riccardo Lencioni; Peter J Littrup; Tito Livraghi; David S Lu; John P McGahan; Maria Franca Meloni; Boris Nikolic; Philippe L Pereira; Ping Liang; Hyunchul Rhim; Steven C Rose; Riad Salem; Constantinos T Sofocleous; Stephen B Solomon; Michael C Soulen; Masatoshi Tanaka; Thomas J Vogl; Bradford J Wood; S Nahum Goldberg
Journal:  J Vasc Interv Radiol       Date:  2014-10-23       Impact factor: 3.464

5.  Pathologic Diagnosis and Genetic Analysis of Sequential Biopsy Following Coaxial Low-Power Microwave Thermal Coagulation For Pulmonary Ground-Glass Opacity Nodules.

Authors:  Jiachang Chi; Min Ding; Zhi Wang; Hao Hu; Yaoping Shi; Dan Cui; Xiaojing Zhao; Bo Zhai
Journal:  Cardiovasc Intervent Radiol       Date:  2021-04-06       Impact factor: 2.740

6.  Serum inflammatory factors and circulating immunosuppressive cells are predictive markers for efficacy of radiofrequency ablation in non-small-cell lung cancer.

Authors:  T Schneider; A Sevko; C P Heussel; L Umansky; P Beckhove; H Dienemann; S Safi; J Utikal; H Hoffmann; V Umansky
Journal:  Clin Exp Immunol       Date:  2015-04-15       Impact factor: 4.330

Review 7.  The management of the advanced colorectal cancer: management of the pulmonary metastases.

Authors:  Charalambos Zisis; Kosmas Tsakiridis; Ioanna Kougioumtzi; Paul Zarogoulidis; Kaid Darwiche; Nikolaos Machairiotis; Bojan Zaric; Nikolaos Katsikogiannis; Georgios Kesisis; Aikaterini Stylianaki; Zhigang Li; Konstantinos Zarogoulidis
Journal:  J Thorac Dis       Date:  2013-09       Impact factor: 2.895

8.  Measuring the Integration of Stereotactic Ablative Radiotherapy Plus Surgery for Early-Stage Non-Small Cell Lung Cancer: A Phase 2 Clinical Trial.

Authors:  David A Palma; Timothy K Nguyen; Alexander V Louie; Richard Malthaner; Dalilah Fortin; George B Rodrigues; Brian Yaremko; Joanna Laba; Keith Kwan; Stewart Gaede; Ting Lee; Aaron Ward; Andrew Warner; Richard Inculet
Journal:  JAMA Oncol       Date:  2019-05-01       Impact factor: 31.777

9.  Video-assisted radiofrequency ablation for pleural disseminated non-small cell lung cancer.

Authors:  Yaxing Shen; Ming Zhong; Wei Jiang; Hong Fan; Hao Wang; Qun Wang
Journal:  BMC Surg       Date:  2013-06-13       Impact factor: 2.102

10.  Ki 67 is an independent predictive biomarker of cancer specific and local recurrence-free survival after lung tumor ablation.

Authors:  Constantinos T Sofocleous; Sandeep K Garg; Perry Cohen; Elena N Petre; Mithat Gonen; Joseph P Erinjeri; Robert J Downey; William D Travis; Stephen B Solomon
Journal:  Ann Surg Oncol       Date:  2013-07-30       Impact factor: 4.339

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.